International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma

Aarnoutse, Rob E.; Wissen, C.P.W.G.M. Verwey-van; Kolmer, E.W.J. van Ewijk-Beneken; Wuis, E.W.; Koopmans, P.P.; Burger, David M.

doi:10.1128/aac.46.3.884-886.2002

Cited by 38 publications

(24 citation statements)

References 5 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…During the course of assay application; inter-assay variation for ATV and RTV was ≤15%. Verification of accuracy for analyte concentrations was performed in conjunction with the ACTG and International Proficiency Testing Programs (Aarnoutse et al, 2002;Droste et al, 2003;Holland et al, 2006).…”

Section: Biochemical Assaysmentioning

confidence: 99%

Interaction between buprenorphine and atazanavir or atazanavir/ritonavir

McCance‐Katz

Moody

Morse

et al. 2007

Drug and Alcohol Dependence

View full text Add to dashboard Cite

Opioid addiction and HIV disease frequently co-occur. Adverse drug interactions have been reported between methadone and some HIV medications, but less is known about interactions between buprenorphine, an opioid partial agonist used to treat opioid dependence, and HIV therapeutics. This study examined drug interactions between buprenorphine and the protease inhibitors atazanavir and atazanavir/ritonavir. Opioid-dependent, buprenorphine/naloxonemaintained, HIV-negative volunteers (n=10 per protease inhibitor) participated in two 24-hour sessions to determine pharmacokinetics of (1) buprenorphine and (2) buprenorphine and atazanavir (400 mg daily) or atazanavir/ritonavir (300/100 mg daily) following administration for 5 days. Objective opiate withdrawal scale scores and Mini-Mental State Examination were determined prior to and following antiretroviral administration to examine pharmacodynamic effects. Pharmacokinetics of atazanavir and atazanavir/ritonavir were compared in subjects and matched, healthy controls (n=10 per protease inhibitor) to determine effects of buprenorphine. With atazanavir and atazanavir/ritonavir, respectively concentrations of buprenorphine (p<0.001, p<0.001), norbuprenorphine (p=0.026, p=0.006), buprenorphine glucuronide (p=0.002, p<0.001), and norbuprenorphine glucuronide (NS, p=0.037) increased. Buprenorphine treatment did not significantly alter atazanavir or ritonavir concentrations. Three buprenorphine/naloxonemaintained participants reported increased sedation with atazanavir/ritonavir. Atazanavir or atazanavir/ritonavir may increase buprenorphine and buprenorphine metabolite concentrations and might require a decreased buprenorphine dose.

show abstract

Section: Biochemical Assaysmentioning

confidence: 99%

Interaction between buprenorphine and atazanavir or atazanavir/ritonavir

McCance‐Katz

Moody

Morse

et al. 2007

Drug and Alcohol Dependence

View full text Add to dashboard Cite

show abstract

“…The within-run variability for 3 replicative analyses of the quality control samples was less than 9.7% for both NFV and RIT. This assay has been cross-validated as part of the International Interlaboratory Quality Control Program for Therapeutic Drug Monitoring in HIV Infection (47). To determine a dosing regimen that would result in relevant plasma concentrations, we treated 6-to 8-week-old BALB/c and C57BL/6 mice with 250 mg/kg of NFV (Agouron Pharmaceuticals Inc.) every 8 hours, yet plasma concentrations were undetectable 6 hours after dosing.…”

Section: Mouse Treatmentsmentioning

confidence: 99%

Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor

Weaver

Tarze²,

Moffat³

et al. 2005

J. Clin. Invest.

View full text Add to dashboard Cite

Inhibitors of HIV protease have been shown to have antiapoptotic effects in vitro, yet whether these effects are seen in vivo remains controversial. In this study, we have evaluated the impact of the HIV protease inhibitor (PI) nelfinavir, boosted with ritonavir, in models of nonviral disease associated with excessive apoptosis. In mice with Fas-induced fatal hepatitis, Staphylococcal enterotoxin B-induced shock, and middle cerebral artery occlusion-induced stroke, we demonstrate that PIs significantly reduce apoptosis and improve histology, function, and/or behavioral recovery in each of these models. Further, we demonstrate that both in vitro and in vivo, PIs block apoptosis through the preservation of mitochondrial integrity and that in vitro PIs act to prevent pore function of the adenine nucleotide translocator (ANT) subunit of the mitochondrial permeability transition pore complex.

show abstract

“…By subtracting 100% from these percentages, the percentage bias from the true concentration (inaccuracy) was calculated. 20% limits around the true values were considered to be appropriate threshold values for satisfactory measurements, as used and justified in our other international QC programmes [12,13]. All participants were informed about their performance within 2 months of reporting their results.…”

Section: −80mentioning

confidence: 99%

“…For comparison, first rounds of similar programmes for antiretroviral drugs and antifungal drugs yielded satisfactory measurements in 65% and 77% of the measurements, respectively [12,13]. One out of six (17%) measurements of TB drugs was still inaccurate and such figures are relevant in the context of pharmacokinetic studies and TDM.…”

Section: −80mentioning

confidence: 99%

An interlaboratory quality control programme for the measurement of tuberculosis drugs

Aarnoutse

Sturkenboom

Robijns³

et al. 2015

Eur Respir J

Self Cite

View full text Add to dashboard Cite

Tuberculosis (TB) remains a major global health problem. Inadequate exposure to TB drugs constitutes one of the main factors underlying suboptimal treatment response and development of resistance, as evidenced by results from: the in vitro hollow fibre model [1]; clinical studies on relationships between drug concentrations and response [2-5]; a pharmacogenetic trial [6]; and a recent meta-analysis [7].More specifically, these concentration-effect evaluations suggest that clinicians should prescribe higher doses of rifampicin [2,5], that acetylator status should be used to determine the dose of isoniazid [6,7], and that higher doses and exposures to pyrazinamide may increase efficacy [4,5].Clearly, such studies also underline the relevance of careful concentration-effect evaluations during the development of new TB drugs that will eventually be applied by clinicians all over the world.Finally, these studies support the concept of therapeutic drug monitoring (TDM) of TB drugs as applied by clinicians and pharmacists in selected centres around the world [8][9][10]. In contrast to administering the same fixed dose to all patients, TDM seeks to individualise drug doses, guided by measurement of serum (or plasma) drug concentrations.

show abstract

International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma

Cited by 38 publications

References 5 publications

Interaction between buprenorphine and atazanavir or atazanavir/ritonavir

Interaction between buprenorphine and atazanavir or atazanavir/ritonavir

Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor

An interlaboratory quality control programme for the measurement of tuberculosis drugs

Contact Info

Product

Resources

About